Phase I and pharmacologic study of topotecan in patients with impaired renal function

Journal of Clinical Oncology

Volumn 14, Issue 12, 1996, Pages 3062-3073

  O'Reilly, S ^a   Rowinsky, E K ^a   Slichenmyer, W ^a   Donehower, R C ^a   Forastiere, A A ^a   Ettinger, D S ^a   Chen, T L ^a   Sartorius, S ^a   Grochow, L B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LACTONE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MALE; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0029966916     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.12.3062     Document Type: Article

References (32)

1. Wall ME, Wani MC: Camptothecin and taxol: Discovery to clinic - Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753-760, 1995
2. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of the camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
3. Rowinsky EK, Adjei AA, Donehower RC, et al: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
4. Rowinsky E, Grochow L, Hendricks C, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
5. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan 24hr continuous infusion weekly. Cancer Res 54:1220-1226, 1994
6. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors. J Natl Cancer Inst 85:1499-1507, 1993
7. van Warmerdam LJC, Verweij J, Schellens JHM, et al: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35:237-245, 1995
8. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Disp 20:706-713, 1992
9. Topotecan Investigators Brochure. SmithKline Beecham Pharmaceuticals, King of Prusssia, PA, 1994
10. van Warmerdam LJC, ten Bokkel WW, Rodenhuis S, et al: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 13: 1768-1776, 1995
11. Stewart CF, Baker SD, Heideman RL, et al: Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954, 1994
12. O'Reilly S, Rowinsky E, Slichenmyer W, et al: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88:817-824, 1996
13. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
14. Jelliffe RW: Creatinine clearance: Bedside estimate. [letter] Ann Intern Med 79:604-605, 1973
15. Metzler CM: Extended least squares for pharmacokinetic models. J Pharm Sci 76:565-571, 1987
16. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
17. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokin Biopharm 6:539-546, 1978
18. Charter MK: The estimate of moments: A technical note. J Pharmacokin Biopharm 17:203-208, 1989
19. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications (ed 3). Media, PA, Williams & Wilkins, 1995, pp 340-366
20. Altman DG: Practical Statistics for Medical Research (ed 1). London, United Kingdom, Chapman and Hall, 1991
21. Matzke GR, Millikin SP: Influence of renal function and dialysis on drug disposition, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principals of Drug Monitoring (ed 3). Applied Therapeutics Inc, Vancouver, WA, 1992, pp 1-49
22. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function. Clin Chem 38:1933-1953, 1992
23. Tsubaki T, Goodin S, Leader WG, et al: Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 12:685-690, 1993
24. Daugaard G, Rossing N, Rorth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21:163-167, 1988
25. Liliemark J, Peterson C: Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet 21:213-231, 1991
26. Benjamin RS, Wiernick PH, Bachur NR: Doxorubicin chemotherapy - Efficacy, safety, and pharmacologic basis of an intermittant single high dose schedule. Cancer 33:19-27, 1973
27. Brenner DE, Wiernick PH, Wesley M, et al: Acute doxorubicin toxicity. Relationship to pretreatment liver function, response and pharmacokinetics in patients with acute non-lymphocytic leukemia. Cancer 53:1042-1048, 1984
28. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
29. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II)analogue diamine cyclo butane dicarboxylatoplatinum. Cancer Res 45:6502-6506, 1985
30. Siddik ZH, Newell DR, Boxall FE, et al: The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36:1925-1932, 1987
31. D'Incali MD, Rossi C, Zucchetti M, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566-2571, 1986
32. Rowinsky E, Grochow L, Kaufmann S, et al: Sequence dependant effects of topotecan and cisplatin in a phase I and pharmacokinetic study. Proc Amer Soc Clin Oncol 13:142, 1994 (abstr 361)